Anthera Pharmaceuticals (NASDAQ:ANTH) released its earnings results on Monday. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.09, Bloomberg Earnings reports.
Shares of Anthera Pharmaceuticals (NASDAQ ANTH) opened at $2.68 on Wednesday. Anthera Pharmaceuticals has a one year low of $1.20 and a one year high of $6.00.
ANTH has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research note on Tuesday, February 13th. HC Wainwright restated a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Tuesday. Roth Capital initiated coverage on shares of Anthera Pharmaceuticals in a research note on Wednesday, February 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. Anthera Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.38.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.